Drug Trial Radar · NCT07593404
Evaluation of a Novel Ocular Lubricating Eye Drop
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
May 28, 2026
Primary completion
Nov 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Pleryon Therapeutics (Hangzhou) LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- University of Waterloo
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this 2-part study is to assess the safety and tolerability of the new ocular lubricating drop ABR2 during short-term use in subjects for the temporary relief of ocular discomfort due to dryness of the eye. In Part 1, participant will receive 1 drop of ABR2 in one eye and through assessments over a 1-hour period. In Part 2, participant will use 1 drop of ABR2 at least two times a day for 28-day period (may use up to 4 times a day as needed) This is a single arm, open label study with no placebo or comparative arm.
Conditions
- Dry Eye Syndrome (DES)
Interventions
Part 2 ABR2 At least twice a day for 28 daysDrug
Use ABR2 at least BID, up to QID for 28 days
Part 1: ABR2 single dose in one eyeDrug
Receive a single dose in one eye only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Adverse EventsTime frame: At the end of Part 1: 60 minutes after single drop monocular instillation and At the end of Part 2 (after 28 days of bilateral use)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre for Ocular Research & Education, School of Optometry & Vision Science, University of Waterloo
Waterloo, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.